129 related articles for article (PubMed ID: 2188044)
1. [Terguride in hyperprolactinemia--experiences with 5 patients].
Wüster C; Scholz A; Schmelzle A; Horowski R; Ziegler R
Klin Wochenschr; 1990 Apr; 68(7):384-7. PubMed ID: 2188044
[TBL] [Abstract][Full Text] [Related]
2. Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride.
Dallabonzana D; Liuzzi A; Oppizzi G; Cozzi R; Verde G; Chiodini P; Rainer E; Dorow R; Horowski R
J Clin Endocrinol Metab; 1986 Oct; 63(4):1002-7. PubMed ID: 3745401
[TBL] [Abstract][Full Text] [Related]
3. Terguride as a new anti-hyperprolactinemic agent: characterization in rats and dogs in comparison with bromocriptine.
Mizokawa T; Akai T; Nakada Y; Yamaguchi M; Nakagawa H; Hasan S; Rettig KJ; Wachtel H
Jpn J Pharmacol; 1993 Nov; 63(3):269-78. PubMed ID: 7906316
[TBL] [Abstract][Full Text] [Related]
4. Effect of terguride on prolactin levels in normal, puerperal and hyperprolactinaemic women.
Venturini PL; Horowski R; Valenzano M; Costantini S; Fasce V; Gorlero F; Rainer E; De Cecco L
Eur J Clin Pharmacol; 1986; 30(2):195-7. PubMed ID: 3709645
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of oral terguride in patients with a prolactinoma.
Lapka R; Marek J; Rejholec V; Franc Z
Eur J Clin Pharmacol; 1986; 30(3):363-5. PubMed ID: 3732377
[TBL] [Abstract][Full Text] [Related]
6. Terguride in the treatment of hyperprolactinemia.
Vĕtr M; Talas M; Pohanka J; Gazárek F; Fingerová H
Acta Univ Palacki Olomuc Fac Med; 1990; 125():155-60. PubMed ID: 2150271
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetic/pharmacodynamic analysis of anti-hyperprolactinemic effect of terguride based on dopamine D2 receptor occupancy].
Yamada Y; Irizuki N; Takayanagi R; Yamamoto K; Sawada Y; Iga T
Yakugaku Zasshi; 2003 Apr; 123(4):255-60. PubMed ID: 12704865
[TBL] [Abstract][Full Text] [Related]
8. Terguride--a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine.
Ciccarelli E; Touzel R; Besser M; Grossman A
Fertil Steril; 1988 Apr; 49(4):589-94. PubMed ID: 3127243
[TBL] [Abstract][Full Text] [Related]
9. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
Colao A; Sarno AD; Cappabianca P; Briganti F; Pivonello R; Somma CD; Faggiano A; Biondi B; Lombardi G
Eur J Endocrinol; 2003 Mar; 148(3):325-31. PubMed ID: 12611613
[TBL] [Abstract][Full Text] [Related]
10. Cabergoline in the long-term therapy of hyperprolactinemic disorders.
Ferrari C; Paracchi A; Mattei AM; de Vincentiis S; D'Alberton A; Crosignani P
Acta Endocrinol (Copenh); 1992 Jun; 126(6):489-94. PubMed ID: 1642081
[TBL] [Abstract][Full Text] [Related]
11. Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly.
Dallabonzana D; Liuzzi A; Oppizzi G; Verde G; Chiodini PG; Dorow R; Horowski R
J Endocrinol Invest; 1985 Apr; 8(2):147-51. PubMed ID: 4031381
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia.
Buyukbayrak EE; Karageyim Karsidag AY; Kars B; Balcik O; Pirimoglu M; Unal O; Turan C
Arch Gynecol Obstet; 2010 Nov; 282(5):561-6. PubMed ID: 20571820
[TBL] [Abstract][Full Text] [Related]
14. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders.
Ferrari C; Mattei A; Melis GB; Paracchi A; Muratori M; Faglia G; Sghedoni D; Crosignani PG
J Clin Endocrinol Metab; 1989 Jun; 68(6):1201-6. PubMed ID: 2656736
[TBL] [Abstract][Full Text] [Related]
15. [Medical treatment of hyperprolactinemic states using lisuride, a prolonged-action dopaminergic].
Zárate A; Fonseca ME; Moran C; Miranda R
Gac Med Mex; 1988; 124(3-4):107-9. PubMed ID: 2905312
[No Abstract] [Full Text] [Related]
16. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.
Cannavò S; Curtò L; Squadrito S; Almoto B; Vieni A; Trimarchi F
J Endocrinol Invest; 1999 May; 22(5):354-9. PubMed ID: 10401709
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
18. Suppression of puerperal lactation by terguride. A double-blind study.
Venturini PL; Horowski R; Fasce V; Valenzano M; Ferreri C; Badino G; Rainer E; Scholz A; De Cecco L
Gynecol Obstet Invest; 1988; 26(1):33-8. PubMed ID: 3049266
[TBL] [Abstract][Full Text] [Related]
19. Prolactinomas.
Friedman TC
N Engl J Med; 2004 Mar; 350(10):1054-7; author reply 1054-7. PubMed ID: 14999121
[No Abstract] [Full Text] [Related]
20. Rapid regression of macroprolactinomas by the new dopamine partial agonist terguride.
Gräf KJ; Köhler D; Horowski R; Dorow R
Acta Endocrinol (Copenh); 1986 Apr; 111(4):460-6. PubMed ID: 3085417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
